Vor Biopharma (VOR) AI Stock Analysis

• Market Cap: $261.17M
• Dividend Yield: N/A
• Average Volume (3M): 32.45M
• Price to Earnings (P/E): ―
• Beta (1Y): 4.25
• Revenue Growth: N/A
• EPS Growth: 2.98%
• Country: US
• Employees: 159
• Sector: Healthcare
• Sector Strength: 37
• Industry: Biotechnology
• EPS (TTM): -0.25
• Shares Outstanding: 124,959,520
• 10 Day Avg. Volume: 10,732,013
• 30 Day Avg. Volume: 32,448,460
• PEG Ratio: -0.22
• Price to Book (P/B): 4.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.87
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 10.69
• Enterprise Value/Gross Profit: -290.30
• Enterprise Value/Ebitda: -0.55
• 1Y Price Target: $1.18
• Price Target Upside: -45.62% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7

• Rating: 33 Underperform
• Price Target: ―

Vor Biopharma faces significant financial challenges, with no revenue and ongoing losses. Technical indicators suggest weak market sentiment, and the lack of positive valuation metrics further underscores the risk. Investors should be cautious due to the high financial risk and uncertainty.

Positive Factors

Product Approval

Telitacicept has been successful in the clinic and has received marketing approvals in China for multiple conditions.

Strategic Partnerships

Vor announced an exclusive license agreement with RemeGen Co., Ltd to develop and commercialize telitacicept in ex-Greater China geographies.

Negative Factors

Financial Challenges

A significant reduction in workforce and associated restructuring expenses indicate financial and operational challenges.

Stock Downgrade

Despite having a healthy balance sheet, the uncertainties due to potential strategic alternatives have led to a downgrade of VOR stock to Neutral from Buy.

Workforce Reduction

The company is winding down all clinical and manufacturing operations, retaining only eight essential employees, leading to a workforce reduction of approximately 95%.

Vor Biopharma Business Overview & Revenue Model

Company Description

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Vor Biopharma generates revenue primarily through research and development collaborations, partnerships, and potential future product sales. The company's business model is centered around developing its pipeline of eHSC-based therapies, which are designed to improve the efficacy and safety of existing cancer treatments. Revenue streams may include milestone payments and royalties from strategic partnerships with larger pharmaceutical companies, as well as potential licensing agreements for its proprietary technologies. Additionally, Vor Biopharma may secure funding through government grants or research institutions to support its innovative research initiatives.

Vor Biopharma Financial Statement Overview

Summary

Vor Biopharma demonstrates significant financial strain, with no revenue generation and consistent net losses. The company's balance sheet shows declining equity, and cash flow statements reflect ongoing cash burn problems. These factors collectively point to high financial risk and uncertainty about future viability.

Income Statement

Vor Biopharma has consistently reported zero revenue, indicating a lack of operational income generation. The company has been operating at a loss for several years, with negative EBIT and net income, highlighting significant profitability challenges.

Balance Sheet

The company maintains a moderate debt-to-equity ratio, which suggests limited leverage. However, the continuous decline in stockholders' equity and total assets since 2020 raises concerns about financial stability and sustainability.

Cash Flow

Vor Biopharma's free cash flow has been consistently negative, indicating cash burn issues. The operating cash flow is also negative, suggesting operational inefficiencies and an inability to cover costs without external funding.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-3.49M	-8.96M	-4.45M	-1.39M
EBITDA	-113.39M	-114.37M	-90.89M	-67.58M	-41.95M
Net Income	-116.91M	-117.86M	-90.77M	-68.78M	-43.34M
Balance Sheet
Total Assets	142.89M	198.13M	299.37M	242.59M	75.91M
Cash, Cash Equivalents and Short-Term Investments	91.93M	137.18M	230.25M	207.47M	48.54M
Total Debt	31.83M	35.66M	38.91M	18.01M	18.29M
Total Liabilities	46.23M	47.40M	48.76M	26.33M	27.64M
Stockholders Equity	96.66M	150.72M	250.61M	216.26M	48.27M
Cash Flow
Free Cash Flow	-99.89M	-101.36M	-93.61M	-73.04M	-40.45M
Operating Cash Flow	-99.66M	-100.29M	-85.14M	-69.14M	-36.29M
Investing Cash Flow	96.86M	71.01M	-94.09M	-91.65M	-4.16M
Financing Cash Flow	53.39M	2.94M	117.14M	232.91M	82.53M

Vor Biopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VOR, the sentiment is Positive. The current price of 2.17 is above the 20-day moving average (MA) of 2.02, above the 50-day MA of 0.94, and above the 200-day MA of 0.94, indicating a bullish trend. The MACD of 0.37 indicates Positive momentum. The RSI at 62.21 is Neutral, neither overbought nor oversold. The STOCH value of 22.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VOR.

Vor Biopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CCCC	53 Neutral	$162.61M	―	-45.55%	―	98.56%	37.97%
Sector *	52 Neutral	$7.61B	0.10	-63.03%	2.08%	16.34%	0.32%
SNTI	47 Neutral	$51.90M	―	-116.63%	―	-100.00%	24.59%
ZNTL	46 Neutral	$108.65M	―	-59.45%	―	―	48.92%
ELUT	45 Neutral	$83.88M	―	149.62%	―	-18.22%	44.67%
PLRX	37 Underperform	$97.60M	―	-63.22%	―	-100.00%	-26.44%
VOR	33 Underperform	$261.17M	―	-125.43%	―	―	2.98%

Vor Biopharma Corporate Events

Vor Biopharma’s Chief Medical Officer Resigns

On March 31, 2025, Eyal C. Attar, M.D., announced his resignation as Chief Medical Officer of Vor Biopharma Inc., effective April 18, 2025, to pursue a new opportunity. Vor Biopharma plans to enter into a consulting agreement with Dr. Attar for transition services, acknowledging his contributions to the company.

Vor Biopharma Approves Stock Option Repricing Strategy

On February 3, 2025, Vor Biopharma’s board approved a stock option repricing to reduce the exercise price of certain options to $1.34 per share, impacting approximately 6.76 million shares. This move aims to motivate and retain employees while avoiding stock dilution or additional cash outlays, with a retention period set until February 3, 2026 or earlier under specific conditions.